September 07, 2005 14:03 ET

Second-Hand Smoke Kills as Many Women as Active Smoking in China According to New Study; Nymox (NASDAQ: NYMX) TobacAlert™ Product Detects Second-Hand Smoke Exposure

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 7, 2005) -

Exposure to secondhand smoke kills as many women in China as does smoking, according to new study findings by researchers at the University of California, Berkeley. The study estimated that in 2002, 48,400 women in China died from lung cancer and ischemic heart disease attributed to passive smoking, compared with 47,300 lung cancer and heart disease deaths from "active" smoking. The findings were presented at the 10th International Conference on Indoor Air Quality and Climate in Beijing, China, on Monday, September 5. The study also found that of the 12,000 lung cancer deaths in 2002 attributed to passive smoking, 73 percent, or 8,800, were among women. Similarly, women accounted for 84 percent, or 39,600, of the 47,000 ischemic heart disease deaths from passive smoking.

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

A recently published study by researchers at the National Institute of Environmental Health Sciences, the University of Minnesota, and the National University of Singapore, published online in Thorax, of 35,000 adult non-smokers in Singapore has found that those who lived with a smoker during childhood had more than twice as many respiratory problems as those who did not have exposure. A third recent study of 60,182 never-smokers followed over a seven year period found a marked increase in the risk of lung cancer for adults who reported regular exposure to second-hand smoke during childhood (BMJ 2005; 330(7486):277).

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX